SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The community is intensely debating a potential upcoming SpaceX IPO, with widespread skepticism regarding valuations and fears that retail investors are being positioned as exit liquidity for a massive pump-and-dump scheme. While some traders are actively scouting for alternative "proxy" stocks in the aerospace and satellite sectors to capture sector-wide momentum, others are deeply concerned about the sustainability of current space-tech valuations and the impact of extreme hype on market stability.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is currently trending due to its pivotal role in institutional pilot projects, including tokenized deposit initiatives with major global banks. The community is heavily focused on its extremely low supply and perceived utility as essential infrastructure for real-world asset tokenization.

noice

NOICE is trending as traders speculate on its potential for volatility and explosive growth, fueled by its status as a nanocap meme token and recent appearances on trending gainers lists. The community is actively debating its technical setup, sharing hopes for further exchange visibility, and discussing broader market sentiment regarding altcoin season and upcoming regulatory developments.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The Degen community is actively discussing potential upcoming catalysts, including app beta updates and exchange listing rumors, while debating whether current price fluctuations represent a strategic buying opportunity or a pump-and-dump cycle. Sentiment remains polarized as holders look for volume-driven breakouts and sustained momentum to validate the project's long-term social utility goals.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as traders speculate on the potential enterprise and market impact of the upcoming Nasdaq listing of AI Holdings (AIAI), which acquired Constellation Network assets. The community is focused on the project's pivot toward institutional data infrastructure, defense-grade validation, and the broader convergence of blockchain with AI commercialization.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is currently experiencing high volume and increased community interest, with traders actively debating its potential for a massive breakout as it is frequently compared to other volatile, low-market-cap assets. While some enthusiasts point to speculative partnership rumors and technical chart patterns, the community remains divided between those expecting a significant rally and those warning of potential pump-and-dump mechanics.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is experiencing significant market activity driven by positive Phase 3 data for Tyvaso in idiopathic pulmonary fibrosis, which analysts view as a major expansion of its addressable patient population. The community is actively debating the company's long-term competitive positioning against rival inhaled therapies and potential acquisition rumors within the broader respiratory and organ manufacturing sectors.

Glass House Brands, Inc. operates as an integrated cannabis company in the United States with focus on the California market and building brands to serve consumers across various segments. The company is involved in greenhouse cultivation operations, manufacturing practices, brand-building, and retailing activities. The company offers its cannabis products through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. The company was founded by Kyle Kazan, Graham Farrar and Jocelyn Rosenwald in 2015 and is headquartered in Long Beach, CA.

Glass House Brands Inc - Ordinary Shares (sub voting)

Glass House Brands

Glass House Brands is facing intense community scrutiny regarding potential labor and regulatory issues following reports of recent enforcement actions at cultivation facilities. While some investors remain optimistic about the company's long-term production scale and competitive cost structure in the California market, others are increasingly concerned about operational stability and the potential impact on future growth.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is trending as the community debates its potential for a massive breakout, with many traders pointing to its low market cap and historical volatility as catalysts for a major pump. While some investors remain optimistic about a return to previous highs during altseason, others express significant frustration over persistent price stagnation and perceived poor management.

iShares Trust - iShares J.P. Morgan USD Emerging Markets Bond ETF

iShares J.P. Morgan USD Emerging Markets Bond ETF

EMB is trending as traders closely watch emerging market sovereign bond performance amid broader fixed income momentum shifts and cooling inflationary pressure. The community is actively discussing the ETFs role as a diversification tool for income generation, with heightened focus on its price action relative to U.S. Treasuries and potential spread carry opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Mantle cell lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that affects roughly 3,300 new patients annually in the United States.&nbsp;</li><li>Continued approval will depend on confirmatory trials, BeOne said.</li><li>Several popular drugs in the United States have successfully transitioned from the FDA’s accelerated approval pathway to full traditional approval after confirmatory trials.</li></ul>BeOne Medicines (ONC) shares climbed nearly 2% Wednesday after the U.S. Food and Drug Administration granted accelerated approval to the company’s BEQALZI, marking the first new B-cell lymphoma 2 inhibitor approved in nearly a decade and the only one cleared for mantle cell lymphoma.The approval covers adult patients with relapsed or refractory (R/R) mantle cell lymphoma who have received at least two prior lines of systemic therapy. BeOne, formerly BeiGene, described the drug as a next-generation BCL2 inhibitor engineered for greater potency, selectivity, and a pharmacologic profile that could improve efficacy, tolerability, and dosing convenience. BCL-2 inhibitors are a class of targeted cancer therapies that induce cancer cell death by blocking the BCL-2 protein, which otherwise allows cancer cells to evade self-destruction.Mantle cell lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that affects roughly 3,300 new patients annually in the United States.<h2 class="st-heading-2">ONC Approval Data</h2>The accelerated approval was based on data from a study showing an overall response rate of 52% and a complete response rate of 16%, with a median duration of response of 15.8 months. The drug was generally well tolerated, the firm said.Continued approval will depend on confirmatory trials, BeOne said. BEQALZI is already approved in China for this indication and is under review by the European Medicines Agency and other regulators.<h2 class="st-heading-2">Other Accelerated Approval Stories</h2>Several popular drugs in the United States have successfully transitioned from the FDA’s accelerated approval pathway—granted on the basis of surrogate endpoints promising clinical benefit—to full traditional approval after confirmatory trials verified their efficacy and safety. High-profile examples include Merck’s Keytruda, which received accelerated approval in 2017 for microsatellite instability-high or mismatch repair-deficient solid tumors and was converted to full approval in 2023.Yet another name is Bristol Myers Squibb’s Opdivo, accelerated in 2016 for relapsed or refractory classical Hodgkin lymphoma and granted traditional approval in March 2026.<h2 class="st-heading-2">How Did ONC Retail Traders React?</h2>On Stocktwits, retail sentiment around ONC stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user opined that the stock will “retest the highs” it touched earlier this year.<stembedurl>https://www.stocktwits.com/Chartguy2000/message/652858974</stembedurl><a href="https://stocktwits.com/symbol/ONC">ONC stock</a> has gained about 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-draws-attention-as-culper-research-takes-short-position-over-china-ties/cZXLrSBReKF">Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of oncology company BeOne Medicines (BeiGene) is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma

The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday. 

Equity

The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday. 


Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

<ul class="summary-bullets"><li>Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising."</li><li>The firm now awaits additional data in the second half of 2026 to better assess Sarepta's programs.</li></ul>Shares of Sarepta Therapeutics (SRPT) closed 35% higher on Wednesday despite Wall Street raising concerns on the company’s early clinical results for two of its programs in neuromuscular diseases.Leerink analyst Joseph Schwartz said the initial data released by the company earlier on Wednesday in genetic diseases myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy type 1 (FSHD1) are "a bit of a mixed bag." While it seems like they can achieve "impressive" muscle concentration, the DM1 data are "very limited and safety remains an open debate," said the analyst, who has a ‘Market Perform’ rating on Sarepta shares.Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." However, the early nature of data and use of different sample sizes across measurements may bias the results, preventing conclusion, the analyst told investors in a research note. The firm awaits additional data in the second half of 2026 to better assess Sarepta's programs. The firm has an ‘Outperform’ rating on Sarepta with a $37 price target.<h2 class="st-heading-2">Sarepta’s Trial Data</h2>Sarepta said earlier in the day that early results from the studies of its investigational siRNA treatment SRP-1001 in FSHD1 and DM1 demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerability, which the company expects will lead to better clinical efficacy.Both DM1 and FSDH1 are genetic disorders caused by overexpression of mutant proteins or toxic mRNA and characterized by progressive muscle weakness. The experimental treatment is designed to reduce, or knock down, the production of DUX4 protein in skeletal muscle.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has dropped 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP">Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.<h2 class="st-heading-2">Gene Therapy Study Details</h2>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.<h2 class="st-heading-2">Street Consensus</h2>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

<ul class="summary-bullets"><li>The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group.</li><li>ELEVIDYS reduced the rate of functional decline by about 70%.</li><li>ELEVIDYS has been administered to more than 1,200 patients worldwide in both clinical trials and real-world use.</li></ul>Shares of Sarepta Therapeutics (SRPT) jumped 6% in pre-market trading on Monday after the company announced positive three-year topline results from its Phase 3 EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with Duchenne Muscular Dystrophy (DMD).SRPT shares gained further after the opening bell, trading 12% higher at the time of writing.The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group. Three years after treatment, patients maintained North Star Ambulatory Assessment (NSAA) scores above baseline, while untreated patients showed the expected decline.ELEVIDYS reduced the rate of functional decline by about 70% or more on key measures, including Time to Rise and the 10-meter walk/run, with the treatment effect increasing over time. No new safety concerns were identified, supporting ELEVIDYS’ manageable safety profile.Sarepta said analysis of its three-year data is ongoing and includes functional results from patients who crossed over to treatment and have now been followed for two years.&nbsp;ELEVIDYS is currently the only approved gene therapy for DMD and has been given to more than 1,200 patients worldwide in both clinical trials and real-world use. The therapy is available for ambulatory patients aged four and older under an updated FDA label announced in late 2025.&nbsp;<h2 class="st-heading-2">Latest Updates</h2>Sarepta is working with Roche to broaden global access to the therapy, with Sarepta handling U.S. regulatory approval, manufacturing, and commercialization, and Roche managing approvals and distribution outside the United States.Earlier this month, the company announced the submission of a clinical trial application to New Zealand’s Medsafe for its INSIGHTT study of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington’s disease. If approved, the first-in-human trial is expected to begin in the second quarter of 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/srpt_jpg_4e3ede4352.webp" alt="srpt.jpg">One bullish user said the ‘results are very impressive for a rare disease with no cure’.<stembedurl>https://stocktwits.com/free2dream/message/642864936</stembedurl>Another user added that breaking the $25 resistance mark would be huge. The stock is currently trading around $23.5.<stembedurl>https://stocktwits.com/Sareptaking/message/642878594</stembedurl>The stock has been under heavy selling pressure over the past year, declining more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/traw-stock-slides-in-volatile-session-after-covid-19-treatment-trial-update/cmy7u2BR4hI">TRAW Stock Slides In Volatile Session –&nbsp; What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.   

SRPT Pre-Market Rally Fueled By Promising DMD Therapy Results

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

<ul class="summary-bullets"><li>Shiong added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors.</li><li>Explaining what this means, he said that half of the patients at this stage do not survive beyond six months.</li><li>The Culver City, California-based immunotherapy company stated in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial.</li></ul>ImmunityBio Inc. (IBRX) shares were up more than 5% in Monday’s pre-market trade after a volatile session on Friday following the company’s Phase 2 glioblastoma trial update.The Culver City, California-based immunotherapy company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-volatility-after-immunitybio-phase-2-glioblastoma-trial-update/cmyR7VnR4gk">stated</a> in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial. The company said that as of Jan. 22, 2026, it had enrolled 23 patients in the Phase 2 glioblastoma trial, of which four deaths have been reported so far, while 14 patients have evaluable clinical data.<h2 class="st-heading-2">ImmunityBio Founder Issues Clarification</h2>However, Patrick Soon Shiong, ImmunityBio’s founder,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2015148449059201385">took</a> to X on Saturday to clarify what the update signified.“The fact that we have patients alive still at 12 months and that the ‘median has NOT YET&nbsp; been reached’ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care,” he said.He added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors. Explaining what this means, he said that half of the patients at this stage do not survive beyond the timeframe of six months or longer.<figure class="image"><img src="https://news.stocktwits-cdn.com/Patrick_post_jpg_65b0607bff.webp" alt="Dr. Pat Soon-Shiong's post on X" width="727" height="500"><figcaption>Dr. Pat Soon-Shiong's post on X | @DrPatrick/X</figcaption></figure><h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a> was in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user said that they believe IBRX should trade at a market capitalization of $10 billion, while adding that ImmunityBio represents a “complete shift in standard of care of cancer.” The company’s current market capitalization is $6.35 billion.<stembedurl>https://stocktwits.com/BixbyKnolls/message/642850960</stembedurl>Another user wondered why any investor would not hold the IBRX stock with “so many approvals on the horizon.”<stembedurl>https://stocktwits.com/Nate711/message/642846497</stembedurl><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 226% year-to-date and 107% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-silver-gold-price-rally-people-clueless-slv-gld-etf-soar-pre-market/cmy7FWpR4Wx">Peter Schiff Says Most People Are 'Clueless' And In For A 'Shock' As Gold, Silver Scale New Highs: SLV, GLD ETFs Soar Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund